The Diabetes Teaching Center is proud to announce their new educational mobile app, Diabetes IQ. DiabetesIQ was created by the collaborative efforts of the University of San Francisco Diabetes Teaching Center and QuantiaMD. The mobile application, available for iOS and Android platforms, is an innovative new way for patients to explore their knowledge of the forms, progression, treatment, and complications of diabetes.
UCSF is a proud sponsor of the California Diabetes Summit, the only statewide public health conference that brings together California's preeminent diabetes prevention and control professionals, as well as leaders in policy, systems change, environmental approaches, health communications and health systems. Speakers include faculty members Dean Schillinger, MD, and Robert Lustig, MD. For more information, email
For relatives of people with type 1 diabetes who are not yet diagnosed, but who are at risk for type 1 diabetes, there are now promising clinical trials available. UCSF Pediatric Diabetes Program director Steve Gitelman, MD, suggests that all family members take a simple blood test which screens for the presence of diabetes-related autoantibodies that may appear years before type 1 diabetes develops.
We are pleased to report that the National Institutes of Health awarded Northern California's Kaiser Permanente's Division of Research a Center for Diabetes Translation, with UCSF serving as a key collaborator. As one of seven centers nationwide, the focus will be on diabetes prevention, diabetes health technology and diabetes disparities.
The Diabetes Teaching Center was named a Technical Innovation Finalist in the San Francisco Business Times Health Care Heroes Awards. The award was presented in recognition of the Teaching Center’s innovation in creating Diabetes Education Online, www.deo.ucsf.edu.
Thanks to the ongoing generosity of a very special family, the Joseph and Vera Long Foundation recently endowed the Vera M. Long Outstanding Diabetes Scientist Post-Doctoral Fellowship. The foundation stipulated that the fellowship recipient have an exceptional academic record, potential for scientific advancement and demonstrated interest in promoting the advancement of women in science.
Thanks to the generous support of a member of our Diabetes Center’s Leadership Council, we’ve brought diabetes to the forefront at UCSF through the recently-created UCSF Diabetes Family Fund for Innovative Patient Care, Education and Scientific Discovery. This fund seeks to stimulate and support creative, collaborative and imaginative innovations and projects whose outcomes and discoveries are transformative.
A talented young researcher has joined our team to help tackle the growing epidemics of obesity, insulin resistance and the metabolic syndrome. Shingo Kajimura, PhD, is an accomplished researcher in the regulation of fat cell development and the molecular networks involved in the development of obesity-linked diseases such as type 2 diabetes.
The UCSF Diabetes Family Fund for Innovative Patient Care, Education and Scientific Discovery made its first round of awards in March. Eleven groups of collaborators were selected from a total of 44 proposals. Read more about the broad range of projects that will significantly impact diabetes research, care and education.
Twenty-six million Americans now have type 2 diabetes and nearly 79 million more have pre-diabetes. Genetic defects play a role in causing type 2 diabetes, but for almost all patients these defects have been unknown.
Besides running the Diabetes Center as our Director, Matthias Hebrok, PhD, is one of the world's foremost experts on pancreatic development. Dr. Hebrok and his lab colleagues are studying how the insulin-producing pancreatic islets are formed during organogenesis and how their function is regulated in the mature pancreas. Ultimately, they hope to learn how changes in gene expression may allow islets to regenerate in individuals living with diabetes.
A number of new clinical studies using investigational drugs for type 1 diabetes have been launched by the UCSF Pediatric Diabetes Clinical Research Program under the leadership of Steve Gitelman, MD. Investigational drugs are those that are not approved for use in diabetes by the U.S. Food and Drug Administration (FDA). One novel study involves the immune system’s T cells.
You are invited to attend a presentation, "Rebalancing the Immune System in Type 1 Diabetes Without Drug Therapy: The Promise of Regulatory T Cells" on Wednesday, May 18th, 6 p.m.at the UCSF Medical Center, 513 Parnassus Ave, Room N-225, San Francisco.